Donald Trump says U.S. interest rates are already too high. Markets are increasingly betting that the Federal Reserve chair he appointed will raise them anyway. At 5:20 p.m. EDT on August 31, Trump was asked…
Category:
Business
-
-
PG&E shares lost about one-fifth of their value Monday after California lawmakers produced a wildfire package that left the utility industry’s central liability concerns largely untouched. PCG was trading at $13.27 shortly after the August…
-
Salesforce’s latest earnings did more than rescue a stock that had spent much of the past year under pressure. They reopened a much bigger market question: what if artificial intelligence does not hollow out enterprise…
-
Claudeforce is not an AI feature bolted onto a CRM. That framing, which most of the coverage reached for in the first 24 hours, gets the direction of travel exactly backwards. The larger half of…
-
Kevin Warsh did not give markets the forward guidance they wanted at Jackson Hole. He gave them something more consequential: a much clearer hierarchy of risks. Inflation is first. In his first Jackson Hole keynote…
-
Why Is Schwab Expanding Beyond Bitcoin And Ether? Charles Schwab plans to add Solana, Avalanche and Chainlink to its cryptocurrency trading platform in the coming months, widening its direct digital asset offering beyond Bitcoin and…
-
How Does The Bitcoin-Backed Mortgage Work? Better Mortgage and Coinbase have made their Bitcoin-backed mortgage product generally available, giving U.S. homebuyers a way to use Bitcoin toward a down payment without selling their holdings. The…
-
A federal jury convicted Las Vegas business owner Brent C. Kovar on Monday for defrauding at least 400 investors of $24 million through a cryptocurrency Ponzi scheme, exposing him to a statutory maximum of 280…
-
Treasury Secretary Scott Bessent unveiled a sweeping new campaign of economic sanctions against Iran on Monday, threatening to cut off dollar access to any country or institution that helps Tehran and predicting a major financial…
-
Moderna (NASDAQ: MRNA) gave back a large piece of its historic cancer-vaccine surge on Thursday, falling about 24% to $133.32, according to on-chain data, a day after it soared 177% on the first positive Phase…